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Pharmacological preconditioning 
with gemfibrozil preserves cardiac 
function after heart transplantation
Kálmán Benke1, Csaba Mátyás1, Alex Ali Sayour1, Attila Oláh1, Balázs Tamás Németh  1, 
Mihály Ruppert1, Gábor Szabó2, Gábor Kökény3, Eszter Mária Horváth4, István Hartyánszky1, 
Zoltán Szabolcs1, Béla Merkely1 & Tamás Radovits1
While heart transplantation (HTX) is the definitive therapy of heart failure, donor shortage is emerging. 
Pharmacological activation of soluble guanylate cyclase (sGC) and increased cGMP-signalling have 
been reported to have cardioprotective properties. Gemfibrozil has recently been shown to exert sGC 
activating effects in vitro. We aimed to investigate whether pharmacological preconditioning of donor 
hearts with gemfibrozil could protect against ischemia/reperfusion injury and preserve myocardial 
function in a heterotopic rat HTX model. Donor Lewis rats received p.o. gemfibrozil (150 mg/kg body 
weight) or vehicle for 2 days. The hearts were explanted, stored for 1 h in cold preservation solution, 
and heterotopically transplanted. 1 h after starting reperfusion, left ventricular (LV) pressure-volume 
relations and coronary blood flow (CBF) were assessed to evaluate early post-transplant graft function. 
After 1 h reperfusion, LV contractility, active relaxation and CBF were significantly (p < 0.05) improved 
in the gemfibrozil pretreated hearts compared to that of controls. Additionally, gemfibrozil treatment 
reduced nitro-oxidative stress and apoptosis, and improved cGMP-signalling in HTX. Pharmacological 
preconditioning with gemfibrozil reduces ischemia/reperfusion injury and preserves graft function in a 
rat HTX model, which could be the consequence of enhanced myocardial cGMP-signalling. Gemfibrozil 
might represent a useful tool for cardioprotection in the clinical setting of HTX surgery soon.
Although there is a rapid evolution of mechanical circulatory support, heart transplantation (HTX) is still the 
gold standard definitive therapy of end-stage heart failure. Ischemia/reperfusion injury is one of the major deter-
minants of primary graft failure and long-term outcome in HTX1. Possible prevention of such an injury can be 
achieved by a professional transplant team with efficient logistics, developing surgical techniques and novel car-
dioplegic solutions2. On the other hand, pharmacological preconditioning of the donor heart before explantation 
is a possible approach to reduce ischemia/reperfusion damage of the graft3.
During the reperfusion phase, the myocardium of the implanted graft suffers from biochemical and metabolic 
alterations, including generation of reactive oxygen species (ROS), intracellular calcium overload, energy deple-
tion and acidosis4. There were several attempts to reduce these biochemical changes, however the most prom-
ising novel therapeutic tools modulate the nitric oxide (NO)/soluble guanylate cyclase (sGC)/cyclic guanosine 
monophosphate (cGMP)/protein kinase G (PKG) pathway5.
Under physiological circumstances, NO binds to the haem moiety of sGC, which results in the production of 
cGMP. Furthermore cGMP activates PKG, that phosphorylates the important effectors which play key roles in the 
regulation of vasodilation, inhibition of platelet aggregation and vascular smooth muscle proliferation6. In recent 
studies, cGMP signalling has been implicated in cardioprotective mechanisms in different disease conditions7.
Increased oxidative stress during ischemia/reperfusion leads to the oxidation of sGC, thereby impairing its 
activity and responsiveness to endogenous NO, which mechanism could result in the deterioration of the cGMP 
signalling cascade7.
According to recent experimental data pharmacological activation of sGC could be a promising tool to pre-
vent myocardial oxidative damage8.
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Cinaciguat (BAY 58-2667), a member of the novel drug family of sGC activators has been extensively inves-
tigated and shown to reduce ischemia/reperfusion injury in experimental models of myocardial infarction and 
HTX1,8. In spite of the promising results of the pre-clinical studies, the clinical development of cinaciguat for the 
indication of acute decompensated heart failure had to be prematurely terminated due to its hypotensive side 
effect after acute iv. application9.
Gemfibrozil (GEM) is one of the fibrate drugs, which has been used in the clinical routine for decades for the 
management of combined dyslipidaemia10. The mechanism of action of this drug is the activation of the peroxi-
some proliferator-activated receptor-alpha (PPARα)11, which is a nuclear receptor responsible for the metabolism 
of carbohydrates and fats12. Interestingly Sharina et al.13 described an existing side effect of GEM in 2015, i.e. 
activation of the sGC in an in vitro setup. Although sporadic literature data exist14–16, the possible cardioprotective 
effects of GEM have been poorly investigated.
We aimed at evaluating the potential cardioprotective effects of GEM in a clinically relevant, well established 
rat model of HTX3,17.
Results
Effect of gemfibrozil treatment on routine biochemical laboratory parameters and hemody-
namic indices of donor rats. Gemfibrozil in a dose of 150 mg/kg body weight had no significant (p < 0.05) 
side effect on the kidney and liver parameters in our non-transplanted rats, whereas the total, HDL and LDL 
cholesterol were significantly (p < 0.05) decreased (Table 1). Trigliceride plasma level was also elevated in the 
Gem-nHTX group. Cardiac performance in both systole and diastole, as well as mean arterial pressure of the 
gemfibrozil and vehicle-treated donor animals were comparable (Table 2).
Hemodynamic parameters and coronary vascular function in the graft. After transplantation, 
increasing LV balloon volumes (‘preload’) resulted in elevated LVSP and dP/dtmax, which were both found to 
be significantly increased at the largest preload volumes used in GEM-HTX compared to HTX (Fig. 1A,B). 
Moreover, gemfibrozil treatment led to a similar improvement in diastolic function at higher preload volumes, 
resulting in significantly (p < 0.05) increased dP/dtmin values compared to HTX, reflecting better myocardial 
relaxation (Fig. 1C). Coronary blood flow was also significantly (p < 0.05) increased after 1 h of reperfusion in 
GEM-HTX compared to the HTX group (Fig. 2), confirming significantly better coronary endothelial function 
in our GEM-HTX animals.
Myocardial gene expression. Quantitative RT-PCR from myocardial RNA extracts revealed that relative 
mRNA-expression for protooncogene c-fos was significantly upregulated in the gemfibrozil and vehicle-treated 
transplant group (Fig. 3A). eNOS myocardial mRNA expression was significantly elevated in the GEM-HTX 
group (Fig. 3B). Pharmacological preconditioning with GEM resulted in a significant increase of the mRNA 
expression for cytochrome C and for the antioxidant enzyme SOD2 (Fig. 3C,D).
Myocardial protein expression. Protein expression of sGC β1 was significantly reduced in the 
vehicle-treated transplant group whereas gemfibrozil treatment restored the enzyme’s protein level near to phys-
iological values (Fig. 4A). We detected elevated cleaved caspase-3 protein expression in the control transplant 
group, whereas the application of gemfibrozil significantly reduced the expression of cleaved caspase-3 (Fig. 4B).
Variable nHTX GEM-nHTX p
Albumine (g/l) 39.1 ± 0.3 34.6 ± 0.2 <0.001
Alkaline phosphatase (U/l) 33.2 ± 2.7 41.3 ± 5.6 0.221
GPT (U/l) 35.6 ± 1.6 34.4 ± 0.6 0.482
GOT (U/l) 57.6 ± 2.1 55.8 ± 2.1 0.544
Direct bilirubine (µmol/l) 0.6 ± 0.1 0.4 ± 0.1 0.19
Total bilirubine (µmol/l) 1.3 ± 0.2 0.7 ± 0.1 0.036
Total cholesterol (mmol/l) 2.2 ± 0.1 1.7 ± 0.1 0.024
CK (U/l) 162.5 ± 8.4 163 ± 6.2 0.962
Creatinine (µmol/l) 30.1 ± 1.7 20.5 ± 1.0 <0.001
HDL cholesterol (mmol/l) 2.0 ± 0.1 1.6 ± 0.1 0.004
LDL cholesterol (mmol/l) 0.4 ± 0.1 0.3 ± 0.1 0.039
LDH (U/l) 137.2 ± 16.7 137.5 ± 16.5 0.991
Triglyceride (mmol/l) 0.5 ± 0.1 1 ± 0.1 0.014
Carbamide (mmol/l) 5.4 ± 0.3 5.7 ± 0.3 0.697
Table 1. Biochemical parameters of gemfibrozil and vehicle-treated non-transplanted group. The results of 
biochemical parameters of gemfibrozil- and vehicle-treated non-transplanted groups are shown. The following 
parameters were studied: albumine, alkaline phophatase, glutamate-pyruvate transaminase (GPT), glutamate 
oxaloacetate transaminase (GOT), direct and total bilirubine, total cholesterol, creatine kinase (CK), creatinine, 
high and low-density lipoprotein-cholesterol (HDL, LDL), lactate dehydrogenase (LDH), triglyceride and 
carbamide. Study groups: gemfibrozil-control group (GEM-nHTX), control-group (nHTX).
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Histopathology. The HTX group was associated with increased 3-NT immunoreactivity in LV myocar-
dium referring to pronounced nitro-oxidative stress, which was significantly (p < 0.05) prevented by gemfibrozil 
(Fig. 5A,B). The number of TUNEL-positive nuclei was significantly (p < 0.05) increased in the myocardium after 
transplantation referring to pronounced DNA fragmentation (Fig. 5C), GEM succesfully reduced the ischemia/
reperfusion injury-induced DNA-strand breaks in HTX represented by markedly reduced TUNEL positivity 
(Fig. 5C).
Myocardial and plasma cGMP levels in the donors. Semiquantitative analysis of myocardial cGMP 
levels has shown that there was significantly (p < 0.05) more cGMP in the myocardium of GEM-HTX animals 
than in the other groups (Fig. 5D,E). Similarly, gemfibrozil preconditioning activated sGC and thus increased the 
plasma cGMP levels in GEM-nHTX (Fig. 5F). The increased cGMP level does not seem to be the consequence of 
a difference in NO production in these animals, as total nitrate/nitrite concentration of urine samples were not 
different (Fig. 6).
Platelet activation and recruitment of leukocytes in the myocardium. Essentially no platelets or 
neutrophils were detected in the myocardial tissue of the non-transplanted groups (Fig. 7A). After 1 hour of 
cold ischemic time and reperfusion, increased myocardial P-selectin immunoreactivity was detected reflecting 
platelet activation and leukocyte recruitment in the vasculature of previously ischemic myocardium (Fig. 7A,B). 
However, GEM treatment prevented the increase of P-selectin immunoreactivity in the myocardium after trans-
plantation (Fig. 7B).
Discussion
Our present study is the first to investigate the effect of gemfibrozil on global myocardial ischemia/reperfusion 
injury in an in vivo model of heterotopic rat HTX. Our results show that preconditioning of the donor heart 
with gemfibrozil improves post-transplant systolic and diastolic LV function and increases CBF by attenuating 
ischemia/reperfusion injury of the myocardium.
The gold standard therapy of terminal heart failure is HTX, however the need for donors is constantly increas-
ing18. Due to the long ischemic time of the donor heart, the chance of primary graft failure is higher in the 
early post-operative period. As part of the ischemia/reperfusion injury-related inflammatory response, activated 
neutrophils release a variety of cytotoxic substances such as ROS and proteases. Moreover, they activate mono-
cytes/macrophages that are the main source of inflammatory cytokines in the ischemic heart. Inflammatory 
cytokines released from activated leukocytes directly mediate vascular endothelial dysfunction with subsequent 
myocardial injury and the deterioration of NO-cGMP signalling. Additionally, after a long ischemic transport 
time, the level of ROS massively increases during reperfusion and the increased superoxide production scav-
enges the small amount of remaining NO contributing significantly to the decreased NO bioavailability. The 
NO-sGC-cGMP-PKG pathway has important physiological role in the regulation of cardiac function including 
coronary vasodilation, inhibition of inflammatory pathways, attenuation of oxidative stress and in the modulation 
of cardiac contractility19,20. Recent literature data suggest that restoration of cGMP-PKG signalling has potential 
cardioprotective effects in various cardiac diseases14–16 including HTX-associated ischemia/reperfusion injury1.
Oxidative stress triggers a decrease in sGC expression and activity21. Furthermore, oxidative stress is asso-
ciated with increased expression and activity of PDE-522 which leads to the imbalance in cGMP synthesis and 
degradation. This results in lower cGMP-levels and thus in impaired regulation of cGMP-PKG signalling path-
way23. However, a novel class of drugs, the sGC activators might overcome this issue by preserving the structure, 
function and activity of sGC in nitro-oxidative stress23. Although sGC activation is a promising way to go, these 
compounds have not been approved for clinical use yet. The widely used fibrate gemfibrozil has been recently 
described as a NO- and haem-independent activator of sGC13. Sharina et al. suggested that the mechanism of 
action of gemfibrozil was similar to haem-mimicking sGC-activators, however it was less potent than cinaciguat 
or ataciguat13. The advantage of gemfibrozil is that it has been approved for decades and used in the pharmacolog-
ical management of hyperlipidemia13. According to the above findings, we have observed significantly reduced 
protein level of sGC in the HTX group which might reflect to the increased rate of degradation of the enzyme. 
Gemfibrozil treatment, however, prevented the degradation of sGC that might have resulted in preserved function 
Hemodynamic variables GEM-nHTX nHTX p
Arterial systolic pressure (mmHg) 119.7 ± 3.6 115.4 ± 2.7 0.3739
Arterial diastolic pressure (mmHg) 91.3 ± 3.7 86.5 ± 3.4 0.3620
Mean Arterial Pressure (mmHg) 103.8 ± 4.2 100.5 ± 3.4 0.5488
Body weight (g) 306 ± 7.3 317.3 ± 6.6 0.2707
Heart rate (1/min) 363.3 ± 12.6 370.1 ± 8.5 0.6653
Left ventricular end-systolic pressure (mmHg) 116.9 ± 5.9 113.6 ± 4.0 0.6607
Left ventricular end-diastolic pressure (mmHg) 6.6 ± 0.5 7.8 ± 0.8 0.2446
Left ventricular dP/dtmax (mmHg/s) 7269.5 ± 178.8 7947.1 ± 287.1 0.0630
Left ventricular dP/dtmin (mmHg/s) −9342 ± 307.7 −9052 ± 466.6 0.6237
Table 2. Hemodynamic parameters of gemfibrozil and vehicle-treated non-transplanted group. The results 
of hemodynamic investigation of gemfibrozil- and vehicle-treated non-transplanted groups are shown. Study 
groups: gemfibrozil-control group (GEM-nHTX), control-group (nHTX).
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of sGC in our model. Furthermore, pharmacological preconditioning with gemfibrozil was associated not only 
with signficantly increased plasma cGMP levels in the donor but also it increased myocardial cGMP level after 
HTX without affecting NO production in our animals. This phenomenon might play a key role in the reduction 
of ischemia/reperfusion injury of the graft. Another possible explanation for the above observed effects is that 
the sGC-activator gemfibrozil might improve the synthesis of different antioxidant proteins via PKG-mediated 
processes24. These events could notably contribute to vaso- and cardioprotection in oxidative injury.
Figure 1. Gemfibrozil improves left ventricular systolic and diastolic function of the graft. (A) Maximal left 
ventricular systolic pressure (LVSP), (B) Maximal slope of systolic pressure increment (dP/dtmax), and (C) 
diastolic pressure decrement (dP/dtmin) are shown at different LV (balloon) volumes. Groups: transplant-control 
group (HTX), gemfibrozil + transplant-group (GEM-HTX). *P < 0.05 vs. HTX.
www.nature.com/scientificreports/
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Oxidative and nitrosative stress lead to the formation of peroxynitrite which is a highly reactive molecule that 
can disrupt enzymes and other proteins25. Peroxynitrite can also uncouple eNOS that becomes a dysfunctional 
superoxide-generating enzyme contributing to enhanced oxidative stress26. The myocardial antioxidant enzyme 
SOD2 plays a major role in the elimination of ischemia/repefusion-induced elevation of ROS27. In accordance 
with this, we observed significantly elevated 3-NT staining in HTX, reflecting increased nitro-oxidative stress. 
However, SOD2 mRNA expression increased in the gemfibrozil treated groups, which process might have 
Figure 2. Coronary blood flow measurements. Groups: transplant-control group (HTX), gemfibrozil + transplant- 
group (GEM-HTX). *P < 0.05 vs. HTX.
Figure 3. Myocardial gene expression. Myocardial mRNA expression of (A) c-fos, (B) endothelial nitrite oxide 
synthase (eNOS), (C) cytochrome C (D) superoxide dismutase (SOD)-2. Groups: control-group (nHTX), 
gemfibrozil-control group (GEM-nHTX), transplant-control group (HTX), gemfibrozil + transplant-group 
(GEM-HTX). *p < 0.05 vs. nHTX, #p < 0.05 vs. HTX.
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contributed to the antioxidant effects of the drug. Additionally, the sGC-derived cGMP activates PKG that in turn 
leads to the opening of the mitochondrial ATP-sensitive potassium channels28 and to increased potassium-influx 
into the mitochondrion. This mechanism enables protons to be pumped out for the formation of H+ eletrochem-
ical gradient and thereby it increases mitochondrial ATP-synthesis29. The above mechanism might have played 
a role in the cardioprotective effects of sGC activation by gemfibrozil by the preservation of ATP-synthesis in 
ischemia/reperfusion injury. Moreover, myocardial cytochrome-c (terminal member of the mitochondrial elec-
tron transport chain) was upregulated in the gemfibrozil-treated transplanted group which might indicate that 
gemfibrozil enhances mitochondrial ATP-production.
As a result of increased nitro-oxidative stress and the disturbed myocardial energy balance (including ATP 
depletion) after ischemia/reperfusion, myocardial cell apoptosis and necrosis may occur30. In accordance with 
this, the modulation of the ATP degradation pathways at different levels is an important strategy to reduce tissue 
injury in ischemia/reperfusion31. Additionally, c-fos, a transcription factor of the activator protein-1 family has 
been linked to apoptosis32. Furthermore, caspase 3 has a central role in the execution phase of cell death as it 
is responsible for chromatin condensation and DNA fragmentation26. Agosto M. et colleagues described that 
in ST-segment elevation myocardial infarction (STEMI) the severity of the myocardial injury was correlated 
with the caspase 3 (p17 fragment) serum level33. Our findings are in concordance with the above data, since we 
observed increased number of TUNEL positive cardiomyocyte nuclei (marker of increased DNA fragmentation), 
significantly elevated level of cleaved caspase 3 (marker of caspase 3 activation) and the overexpression of c-fos 
transcription factor in HTX. The sGC activator gemfibrozil, however, has been shown to have anti-apoptotic 
properties in the donor heart by reducing TUNEL positivity and caspase 3 activation. Interestingly, gemfibrozil 
had no effect on c-fos mRNA level which might have been a result of the relative short reperfusion phase.
Heterotopic HTX was used in our study to simulate the clinical conditions of HTX with whole blood reper-
fusion. This method allows an observation time of 60 minutes. Based on literature data, we determined the rep-
erfusion time to 1 h, where the ischemia/reperfusion injury is the most pronounced with subsequent functional 
deterioration of the graft17.
Although heterotopically transplanted hearts in our model beat in an unloaded fashion (no preload), cardiac 
pump function can be reliably assessed with the help of a ballon catheter inserted into the LV of the graft. Both 
systolic and diastolic performance of the LV can be investigated by registering LVSP, dP/dtmax, and dP/dtmin, 
respectively, at different LV (balloon) volumes. The increased slope of the relations between these parameters 
and LV volume demonstrate preserved systolic (contractility) and diastolic function (active relaxation) in the 
GEM-HTX group when compared to controls.
Moreover, GEM treatment resulted in significant improvement of CBF in the treated-HTX group which might 
reflect the vasoprotective properties of the drug. We hypothesize that the activation of sGC34 by gemfibrozil and 
the subsequently enhanced cGMP-PKG signalling promotes multiple phosphorylation of intracellular targets, 
reduce endothelial injury35 and can lower the cellular Ca2+-concentrations that might contribute to vasodila-
tion and vasoprotection36. This vasodilatative effect of gemfibrozil could be responsible for the elevated CBF and 
might lead to a rapid recovery of the stunned myocardium during reperfusion. Additionally, it has been described 
that GEM succesfully reduced the incidence of cardiac allograft vasculopathy after HTX in adults by lowering 
endothelial damage37. Moreover, sGC activation and the possible eNOS reactivation in the coronaries (indicated 
by increased eNOS mRNA expression) and NO production might contributed synergistically to the decreased 
Figure 4. Protein expression of soluble guanylate cyclase (sGC) and cleaved caspase 3. The protein level of (A) 
sGC and (B) cleaved caspase 3 are shown. Groups: control-group (nHTX), gemfibrozil-control group (GEM-
nHTX), transplant-control group (HTX), gemfibrozil + transplant-group (GEM-HTX). *p < 0.05 vs. nHTX, 
#p < 0.05 vs. HTX.
www.nature.com/scientificreports/
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amount of nitro-oxidative stress in our model. Consequently, we observed improved systolic and diastolic func-
tion of the graft after HTX.
In accordance with previous works with other sGC-activators1 we found that GEM did not affect cardiac 
function of healthy control rats. Thus, the improved cardiac function seen in the GEM-HTX group is a specific 
phenomenon, reflecting a protection against the ischemia/reperfusion-associated impairment of myocardial per-
formance, rather than the consequence of some non-specific direct cardiac effects of GEM. Although fibrates 
are described to have potential harmful side effects38, our biochemical results showed no signs of liver, kidney 
or muscle damage in the GEM treated healthy rats. Thus, gemfibrozil could become a safe and useful tool for the 
management of cardiac donors without having substantial side effects on other organs.
Microvascular obstruction is considered to be one of the major manifestations of myocardial 
ischemia-reperfusion injury and is associated with enhanced leukocyte invasion39. P-selectin, a transmem-
brane adhesion molecule (glycoprotein), is constitutively stored in granules of endothelial cells and platelets but 
becomes exposed under pathological circumstances40. P-selectin plays a pivotal role during ischemia-reperfusion 
injury by enhancing leukocyte invasion. Indeed, a previous study found that blockade of P-selectin protected 
against acute renal failure following ischemia-reperfusion injury41. In line with these findings, here we docu-
ment a significantly higher myocardial P-selectin immunoreactivity in non-treated grafts. However, gem-
fibrozil pretreatment was associated with a P-selectin level that was comparable to that of control hearts (i.e. 
non-transplant groups, which did not suffer global cardiac ischemia/reperfusion injury). This may highlight the 
Figure 5. Histological analysis and plasma cGMP analysis. (A) Representative images of nitrotyrosine 
immunohistochemistry. Magnification: 200x, Marker: 50 µm (B) Quantification of nitrotyrosine 
immunohistochemistry. (C) Quantification of TUNEL-positive cardiomyocyte nuclei. (D) Representative 
images and quantification (E) of myocardial cGMP immunohistochemistry. Magnification: 200x, Marker: 
50 µm (F) Quantification of plasma cGMP. Groups: control-group (nHTX), gemfibrozil-control group (GEM-
nHTX), transplant-control group (HTX), gemfibrozil + transplant-group (GEM-HTX). *p < 0.05 vs. nHTX, 
#p < 0.05 vs. HTX.
www.nature.com/scientificreports/
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potent anti-inflammatory effect of the sGC activator gemfibrozil, which could substantially contribute to the 
cardioprotective effect of the drug in the setting of ischemia/reperfusion injury.
Our study have several limitations. First the donor rat hearts are implanted to recipients with ‘healthy’ cir-
culatory system. In that case, the CBF of the graft becomes elevated thus it might partly be responsible for the 
improved myocardial protection after ischemia/reperfusion injury. Besides, ischemia/reperfusion injury is a 
reversible phenomenon in this model and it allows a fast recovery, making it difficult to find differences between 
experimental groups after a certain time of reperfusion. Additionally, the dose of administration of gemfibrozil 
might be different in a clinical setup due to the differences of pharmacokinetic and pharmacodynamic properties 
in rats and in humans.
To conclude, gemfibrozil treatment improves donor heart function in an experimental model of HTX. The 
potential sGC activator properties of gemfibrozil might be in the background of its cardioprotective effects. These 
findings show that pharmacological preconditioning with gemfibrozil could be a promising option to reduce 
ischemia/reperfusion injury and to increase the ischemic time in order to gain enough donor organs for cardiac 
transplantation.
Figure 6. Quantification of total nitrate/nitrite concentration in urine samples. Groups: control-group (nHTX), 
gemfibrozil-control group (GEM-nHTX), transplant-control group (HTX), gemfibrozil + transplant-group 
(GEM-HTX).
Figure 7. Histological analysis of P-selectin immunohistochemistry. (A) Representative images of myocardial 
P-selectin immunohistochemistry. Magnification: 200x, Marker: 50 µm (B) Quantification of myocardial 
P-selectin immunohistochemistry. Groups: control-group (nHTX), gemfibrozil-control group (GEM-nHTX), 
transplant-control group (HTX), gemfibrozil + transplant-group (GEM-HTX). *p < 0.05 vs. nHTX, #p < 0.05 
vs. HTX.
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Methods
Animals. Male Lewis rats (250–350 g; Charles River, Germany) were housed in a room at 22 ± 2 °C under 
12-h light/dark cycles and were fed a standard laboratory rat diet and water ad libitum. The rats were acclimatized 
for at least 1 week before experiments. All animals received humane care in compliance with the “Principles 
of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the 
Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and used by 
the National Institutes of Health (Guide for the Care and Use of Laboratory Animals, published by the US 
National Institutes of Health [Eighth Edition] the National Academy Press. 2011 and directive 2010/63/EU of the 
European parliament and of the council on the protection of animals used for scientific purposes. Official Journal 
of the European Union. 2010). All procedures and handling of the animals during the study were reviewed and 
approved by the Ethical Committee of Hungary for Animal Experimentation.
Experimental groups. Rats were randomly divided into four groups: (1) control-group (nHTX, n = 8): 
donor rats received methylcellulose vehicle and hearts were not transplanted (2) gemfibrozil-control group 
(GEM-nHTX, n = 8): donor rats received gemfibrozil and hearts were not transplanted (3) transplant-control 
group (HTX): donor rats (n = 8) received methylcellulose vehicle, then hearts were transplanted into the recip-
ients (n = 8) and (4) gemfibrozil + transplant-group (GEM-HTX): donor rats (n = 8) received gemfibrozil, then 
hearts were transplanted into the recipients (n = 8). Donor rats were preoperatively treated orally with vehicle or 
gemfibrozil while recipient rats received no treatment.
Drug application. GEM was purchased from Sigma-Aldrich (Taufkirchen, Germany), suspended in 1% 
methylcellulose solution vehicle and administered via oral gavage at the dose of 150 mg/kg body weight (BW). 
The application started two days before explantation twice a day (8:00 AM and 08:00 PM) and one dose an 
hour before the procedure. This dose and administration method have been determined according to the phar-
macokinetic and –dynamic properties42 of gemfibrozil as well as to the results of previous rodent and human 
experiments13,43,44.
Rat model of heart transplantation. Rat model of heart transplantation was performed as described 
previously17,45. Transplantations were performed in isogenic Lewis to Lewis rats in order to avoid possible organ 
rejection. Briefly, the donor rats were anaesthetized with isoflurane and heparinized (25000 IU iv). A bilateral 
thoracotomy was performed to expose the heart. After cardiac arrest the superior and inferior caval veins and 
the pulmonary veins were tied en masse with a suture and the heart was excised with the aortic arch for future 
measurement of the coronary blood flow (CBF). After excision hearts were stored in cold cardioplegic solution 
(Custodiol, 4 °C, Dr. Franz Köhler Chemie GmbH, Bensheim, Germany). The recipient rats were anaesthetized 
with isoflurane and then heparinized (400 IU/kg iv) and the body temperature was maintained at 37 °C on a 
heating pad. Approximately two-centimeter segments of the infrarenal aorta and the caval vein were isolated and 
occluded by small-vessel forceps. The aorta and the pulmonary artery of the donor heart were anastomosed end 
to side to the abdominal aorta and the vena cava of the recipient rat, respectively. The duration of the implantation 
was standardized at 1 h (ischemic period) to minimize variability between experiments. After the completion of 
the anastomoses, heparin was antagonized with protamin (400 IU/kg iv.) and the occlusion was released and the 
heart was then reperfused with blood in situ for 60 minutes.
Biochemical measurements. After hemodynamic measurements of the non-transplanted groups, blood 
samples were collected from the inferior vena cava in tubes pre-rinsed with EDTA. Plasma albumine, alkaline 
phosphatase, glutamate-pyruvate transaminase (GPT), glutamate oxaloacetate transaminase (GOT), high and 
low-density lipoprotein-cholesterol (HDL, LDL), total cholesterol, triglyceride, direct and total bilirubine, car-
bamide, creatinine, creatine kinase (CK) and lactate dehydrogenase (LDH) were measured by automated clinical 
laboratory assays on a Cobas Integra 400 (Roche Diagnostics, Mannheim, Germany) autoanalyzer.
Plasma cGMP levels were determined from the non-transplanted groups by enzyme immunoassay (EIA) 
using a commercial kit (Amersham cGMP EIA Biotrak System, GE Healthcare, Buckinghamshire, UK). Total 
nitrate/nitrite concentration (a marker of whole body NO production) was measured from urine samples using a 
colorimetric kit (Cayman Chemical, Ann Arbor, MI, USA). We followed the protocols supplied by the producers.
Functional measurements in the donor. We compared the effect of the treatment on the hemodynamic 
parameters of the donor heart before explantation as follows. Invasive hemodynamic measurements were car-
ried out with a 2F microtip pressure-conductance microcatheter (SPR-838, Millar Instruments, Houston, TX, 
USA) with modifications as described previously46,47. Animals were anesthetized with isoflurane (1–2%). Rats 
were placed on heating pads to maintain core temperature at 37 °C. The left external jugular vein was cannulated 
with a polyethylene catheter for fluid administration. Firstly, mean arterial blood pressure (MAP) and heart rate 
(HR) were recorded. Thereafter, the catheter was advanced into the left ventricle (LV) under pressure control. 
Signals were recorded at a sampling rate of 1000 samples/s using a pressure-volume (P-V) conductance system 
(MPVS-Ultra, Millar Instruments) and the PowerLab 16/30 data acquisition system (AD Instruments, Colorado 
Springs, CO, USA). We used a special P-V analysis programme (PVAN, Millar Instruments) to calculate mean 
arterial pressure (MAP), maximal LV end-systolic pressure, LV end-diastolic pressure, maximal slope of systolic 
pressure increment (dP/dtmax) and diastolic pressure decrement (dP/dtmin).
Functional measurements in the graft. One hour after transplantation a 3F latex balloon catheter 
(Edwards Lifesciences Corporation, Irvine, CA, USA) was introduced into the left ventricle via the apex to deter-
mine maximal left ventricular (LV) systolic pressure (LVSP), maximal slope of the systolic pressure increment 
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(dP/dtmax) and diastolic pressure decrement (dP/dtmin) and heart rate (HR) by a Millar micromanometer (SPR-
838, Millar Instruments) at different LV volumes (20–160 µl). From these data LV pressure-volume relationships 
were constructed. Coronary blood flow (CBF) of the graft was measured by an ultrasonic flow meter (Transonic 
Systems Inc., Ithaca,USA) mounted on the donor ascending aorta.
Quantitative real-time polymerase chain-reaction (PCR). Frozen LV samples were homogenized, 
total RNA was isolated as described previously46. Reverse transcription was performed and cDNA samples were 
amplified on the StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using 
TaqMan® Universal PCR MasterMix and TaqMan® Gene Expression Assays (Applied Biosystems) for the follow-
ing targets: c-fos (Rn02396759_m1) a transcription factor, cytochrome-c (Rn00470541_g1) a terminal member of 
the mitochondrial electron transport chain, members of different antioxidant systems like superoxide dismutase 
(SOD-2; Rn00690587_g1), and the endothelial nitrite oxide synthase (eNOS; Rn02132634_s1). Gene expression 
data were normalized to Ribosomal Protein L27 (RPL27; rn00821099_g1) as housekeeping gene. The mRNA 
expression levels were calculated using the CT comparative method (2−ΔCT) and adjusted to a pool of nHTX 
group.
Western blot analysis. LV tissue samples were homogenized, protein concentration was determined as 
described previously46 and equal amounts of protein were separated via gel-electrophoresis. Proteins were trans-
ferred to nitrocellulose membranes. After blocking, membranes were incubated with primary antibodies against 
sGC (1:1000 SAB4501344, Sigma-Aldrich, Budapest, Hungary) and caspase-3 (1:2000, Cell Signaling Technology, 
MA, USA #9662,). After washing, membranes were incubated in horseradish peroxidase-conjugated secondary 
antibody. Immunoblots were developed by enhanced chemiluminescence detection. Protein band densities were 
quantified using GeneTools software (Syngene, Frederick, MD, USA). We have adjusted the protein band densi-
ties to α-tubulin (1:10000, sigma T5168, Sigma-Aldrich, Budapest, Hungary).
Histology, Immunhistochemistry. Hearts were fixed in buffered paraformaldehyde solution (4%), 
embedded in paraffin and 5-μm thick sections were cut. Terminal deoxynucleotidyl transferase-mediated dUTP 
nick end-labeling (TUNEL) reaction was performed (DeadEnd™ Colorimetric TUNEL System, Promega, 
Mannheim, Germany) to detect DNA strand breaks. The nitro-oxidative stress marker 3-nitrotyrosine (3-NT) 
(#10189540, Cayman Chemical, Ann Arbor, MI, USA) was detected by immunohistochemical staining as pre-
viously described46 and 3-NT positive area was analyzed with Image J (NIH, Bethesda, MD, USA) software. For 
identification of intracellular cGMP (#ab12416, Abcam, Cambridge, UK), immunohistochemistry was performed 
according to a previously described method46.
In case of P-selectin staining, paraffin-embedded sections (5 μm) were rehydrated and incubated with 1% 
hydrogen peroxide. After being rinsed in PBS, the sections were incubated with blocking serum. Immunostaining 
was performed with the use of a mouse polyclonal antibody (Impress Reagent, Vector Laboratories, Peterborough, 
UK)48.
Statistical analysis. Data are expressed as mean ± SEM. Normal distribution was tested by 
Kolmogorov-Smirnov test. In case of normal distribution, one-way ANOVA and Bonferroni post hoc test were 
performed. Where data showed not normal distribution Kruskal-Wallis ANOVA and Dunn’s post hoc test were 
done. In case of hemodynamic data in HTX two-way ANOVA with Bonferroni post hoc test was used. P < 0.05 
was considered statistically significant.
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